See also
Black Lung Benefits Act of 1972
Caplan syndrome

References
External links
Faces of Black Lung - USDHHS on YouTube
NIOSH Mining Topic: Respiratory Diseases
NIOSH Coal Workers Health Surveillance Program
Mine Safety and Health Administration
42CFR27 Specifications of Medical Examinations of Underground Coal Miners
Institute of Occupational Medicines pneumoconiosis research
Subsequent trials in Norway and the US did compare injectable naltrexone to buprenorphine and found them to be similar in outcomes for patients willing to undergo the withdrawal symptoms required prior to naltrexone administration. Nearly 30% of patients in the US trial did not complete induction. In real world settings, a review of more than 40,000 patient records found that while methadone and buprenorphine reduced risk of fatal overdose, naltrexone administration showed no greater effect on overdose or subsequent emergency care than counseling alone.Despite these findings, naltrexones manufacturer and some health authorities have promoted the medicine as superior to methadone and buprenorphine since it is not an opioid and does not induce dependence. The manufacturer has also marketed directly to law enforcement and criminal justice officials, spending millions of dollars on lobbying and providing thousands of free doses to jails and prisons. The technique has been successful, with the criminal justice system in 43 states now incorporating long-acting naltrexone. Many do this through Vivitrol courts that offer only this option, leading some to characterize this as "an offer that cannot be refused." The companys marketing techiques have led to a Congressional investigation, and warning from the FDA about failure to adequately state risks of fatal overdose to patients receiving the medicine.In May 2017, United States Secretary of Health and Human Services Tom Price praised [Vivitrol] as the future of opioid addiction treatment after visiting the companys plant in Ohio.